ClinicalTrials.gg
RecruitingNCT07539454Updated Oct 20, 2026

Nirogacestat in Patients With Kaposi Sarcoma

A Phase 2 interventional study of Biospecimen Collection and Chest Radiography in AIDS-Related Kaposi Sarcoma and Skin Kaposi Sarcoma, sponsored by AIDS Malignancy Consortium. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by AIDS Malignancy Consortium · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 20, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium — 2 open to participants now, 2 under way, 1 of them phase 3. AIDS-related Kaposi sarcoma · AIDS Malignancy Consortium.

Started
2026
with 1 other
Phase 2
4 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium, this one is one of 2 that started in 2026, is one of 4 in phase 2, and was the 12th registered.

AIDS-related Kaposi sarcoma

43 studies on the registry are indexed under AIDS-related Kaposi sarcoma; 2 are open to participants now.

Browse AIDS-related Kaposi sarcoma studies →

Open to participants now

2 of the 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1 AIDS-related Kaposi sarcoma study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in AIDS-related Kaposi sarcoma by AIDS Malignancy Consortium, or all of them as a file.
02

Study summary

This phase II trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma (KS). Several anti-cancer drugs work well in treating KS, but there is no treatment that cures KS. Nirogacestat binds to a protein called gamma secretase, which blocks the activation of other proteins called Notch receptors. Blocking these proteins may help keep tumor cells from growing and may kill them. Nirogacestat is a type of gamma secretase inhibitor. Nirogacestat may be effective in shrinking the size of KS lesions and reducing the spread of lesions.

Read the detailed description

PRIMARY OBJECTIVE:

I. Evaluate the efficacy of nirogacestat in terms of overall response (partial response [PR]) or complete response [CR]) of Kaposi sarcoma (KS) tumors.

SECONDARY OBJECTIVES:

I. Evaluate the safety and tolerability of nirogacestat. II. Evaluate the duration of response of KS tumors to nirogacestat. III. Assess the effect of nirogacestat on blood biomarkers such as CD4+ and CD8+ T, CD19+, cell number, human immunodeficiency virus (HIV) and Kaposi sarcoma-associated herpesvirus (KSHV) virus load.

IV. Assess baseline levels of Notch target and regulatory gene products as a target of nirogacestat activity.

EXPLORATORY OBJECTIVES:

I. Assess the effect of nirogacestat on tumor-associated KSHV latent and lytic gene expression.

II. Assess effects of nirogacestat on activation of Notch target genes and Notch regulatory genes.

III. Assess effects of nirogacestat on tumor-associated endothelial-mesenchymal transition.

IV. Assess the pharmacology of nirogacestat in KS patients. V. Assess effects of nirogacestat on tissue biomarkers at progression by single cell transcriptomics or single cell RNA sequencing (scRNAseq).

VI. Assess effects of nirogacestat on tissue biomarkers by multiplex immunohistochemistry (IHC) at baseline and after 28 days of therapy.

OUTLINE:

Patients receive nirogacestat orally (PO) twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo skin biopsy and chest X-ray during screening as well as blood sample collection throughout the study. Patients may also undergo an additional optional skin biopsy on study and computed tomography (CT) throughout the study.

After completion of study treatment, patients are followed every 6 months for 5 years.

03

Conditions studied

  • AIDS-Related Kaposi Sarcoma
  • Skin Kaposi Sarcoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven KS involving skin with or without visceral involvement either newly diagnosed or to or intolerant of one or more prior therapies.
  • Patients must have cutaneous lesion(s) amenable to six total biopsies (minimum size of biopsy to be 4 mm), either six lesions > 4 mm or one large lesion measuring 20 mm that can undergo serial biopsy, and at least five additional lesions measurable for assessment with no improvement over the past month.
  • ≥ 8 g/dL (within three months prior to study entry)
  • (ANC) ≥ 1,000 cells/mm\^3 (within three months prior to study entry)
  • count ≥ 100,000/mm\^3 (within three months prior to study entry)
  • Calculated (method of ) creatinine clearance (CrCl) ≥ 60 mL/min (within three months prior to study entry) (CrCl may also be obtained by the 24-hour collection method at the investigator's discretion)
  • Total should be ≤ 1.5x (ULN) (within three months prior to study entry). If, however, the elevated bilirubin is felt to be secondary to atazanavir therapy, patients will be allowed to enroll on protocol if the total bilirubin is ≤ 3.5 mg/dL provided that the direct bilirubin is normal
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) ≤ 3x ULN (within three months prior to study entry)
  • ≥ 3 months.
  • Ability and willingness to give .
  • Females of (FCBP) must have a negative serum or urine pregnancy test defined as serum Estradiol (E2) > 30 pg/mL, a serum follicle stimulating hormone (FSH) \< 40 mIU/L (measured on Day 3 in regularly menstruating females and age-matched), within 10-14 days prior and again within 24 hours of starting nirogacestat. FCBP must either commit to continued abstinence from heterosexual intercourse or the use of two acceptable methods of , one highly effective method except oral contraceptives and one additional effective method at the same time , at the start of therapy to 7 days after discontinuation of nirogacestat, inclusive. Females and males of will be advised to use effective contraception during treatment with nirogacestat and for 7 days after the last dose. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. Patients must, in the opinion of the investigator, be capable of complying with the protocol.

    • A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
  • All patients with must be on antiretroviral therapy (ART) for HIV infection with > 50/mm\^3 and viral load \< 200 copies/mL. Patients must be on a stable regimen for at least 12 weeks prior to study entry. Patients may receive any Food and Drug Administration (FDA) approved ART except for zidovudine or protease inhibitors.
  • There should be no evidence for improvement in KS in the 3 months prior to study entry for all participants, unless there is evidence for progression of KS in the 4 weeks immediately prior to study entry.
  • If antiretroviral regimen contains zidovudine, efavirenz, etravirine, or protease inhibitors and viral load is suppressed (as measured by HIV viral load ≤ 200/mL), then ART must be adjusted to a less toxic therapy not containing these antivirals and enrollment may proceed without waiting 12 weeks. If on antiviral therapy with zidovudine, efavirenz, etravirine, or protease inhibitors, and viral load is not suppressed (as measured by HIV viral load ≥ 200/mL), then ART must be adjusted to a less toxic regimen allowing for optimal viral suppression and must demonstrate stability for at least 12 weeks prior to study entry.
  • If HIV positive, documentation of HIV-1 or HIV-2 infection by means of any one of the following:

    • Documentation of HIV diagnosis in the medical record by a licensed health care provider.
    • Documentation of receipt of ART (at least two different medications that do not constitute a prescription for pre-exposure prophylaxis) by a licensed health care provider. Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name.
    • HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating > 200 RNA copies/mL.
    • Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as an HIV-1 Western blot confirmation or HIV rapid multi-spot antibody differentiation assay.
  • Age ≥ 18 years. No dosing or adverse event (AE) data are currently available on the use of nirogacestat in participants \< 18 years of age; children are excluded from this study.
  • (ECOG) performance status ≤ 2 ( ≥ 60%).
  • Participants with known history or current symptoms of cardiac disease or history of treatment with cardiotoxic agents should have a clinical risk assessment of cardiac function using the Functional Classification within 3 months before study enrollment. To be eligible for this trial, participants must be Class II or better within 3 weeks before enrollment.

Exclusion criteria

Exclusion Criteria:

  • Concurrent, acute, active opportunistic infection other than oral thrush or genital herpes within 14 days of enrollment.
  • Patients for whom front-line cytotoxic therapy is indicated (i.e., symptomatic visceral or pulmonary KS or symptomatic KS impairing functional status).
  • Concurrent neoplasia requiring cytotoxic therapy.
  • Anti-neoplastic treatment for KS (including chemotherapy, radiation therapy, local therapy including topical 5-FU, biological therapy, or therapy) within four weeks of study entry.
  • Any ongoing treatment (within last three months, lasting longer than 14 days) except for that required for replacement therapy in adrenal insufficiency or inhaled glucocorticoids for the treatment of asthma.
  • Any steroid treatment with equivalent of more than 10 mg prednisone/day lasting longer than 14 days in the last 3 months.
  • Patient is ≤ 2 years free of another primary . Exceptions include the following:

    • Basal cell skin cancer.
    • Cervical carcinoma in situ.
    • Anal carcinoma in situ.
  • Previous local therapy of any KS-indicator lesion unless the lesion has clearly progressed since treatment. Any prior local treatment to indicator lesions regardless of the elapsed time should not be allowed unless there is evidence of clear-cut progression of said lesion.
  • Use of any investigational drug or treatment within four weeks prior to enrollment.
  • Physical or psychiatric conditions that in the estimation of the investigator place the patient at high risk of toxicity or non-compliance.
  • Female patients who are pregnant, lactating, or breast-feeding.
  • Patients requiring blood transfusions to maintain eligibility.
  • Patients currently receiving zidovudine, protease inhibitors, efavirenz, etravirine, ketoconazole, itraconazole, erythromycin, clarithromycin, dexamethasone, phenobarbital, rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, St John's Wort, tacrolimus, cyclosporine, oral , warfarin, docetaxel, sirolimus, or other inhibitors or inducers of or substrates of CYP3A4 that have a narrow therapeutic margin.
  • Patients with CD4 \< 50 mm\^3 and/or viral load ≥ 200 copies/mL.
  • + patients with interval by Fridericia's formula (QTcF) > 480 ms.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Treatment (nirogacestat)

    Patients receive nirogacestat PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo skin biopsy and chest X-ray during screening as well as blood sample collection throughout the study. Patients may also undergo an additional optional skin biopsy on study and CT throughout the study.

    Procedure: Biospecimen Collection · Procedure: Chest Radiography · Procedure: Computed Tomography · Drug: Nirogacestat · Procedure: Skin Biopsy

Interventions

  • ProcedureBiospecimen Collection

    Undergo collection of blood

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureChest Radiography

    Undergo chest X-ray

    Also known as: Chest X-ray

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given PO

    Also known as: (S)-2-(((S)-6,8-Difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide, PF 03084014, PF-03084014, PF03084014

  • ProcedureSkin Biopsy

    Undergo skin biopsy

    Also known as: Biopsy of Skin

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    The ORR will be estimated for each dose group and for all groups combined. The 95% confidence intervals will be constructed for the ORR.

    Time frame: Up to 5 years after completion of study treatment

Secondary outcomes

  1. Incidence of adverse events (AEs)

    The AEs will be tabulated by type, grade, and attribution.

    Time frame: Up to 5 years after completion of study treatment

  2. Duration of the response (DOR)

    Non-responders will be excluded in DOR analysis. Participants who begin treatment but drop out prior to the first post-baseline response assessment will be considered non-responders. The Kaplan-Meier method will be used to describe the DOR for all treated participants. The proportional hazards model will be used to evaluate the association of HIV status and pretreatment status on the DOR.

    Time frame: From the first date on which a partial response or complete response is documented until progression or death due to any cause, assessed up to 5 years after completion of study treatment

  3. Cumulative proportion of study participants still in response

    Will be estimated using the point estimate and the 95% confidence interval using Greenwood's formula for the standard error of the Kaplan-Meier estimate.

    Time frame: At 1 year

  4. Blood biomarkers

    Will assess the effect of nirogacestat on blood biomarkers such as CD4+ and CD8+ T, CD19+, cell number, HIV and Kaposi sarcoma-associated herpesvirus virus load. The analysis of variance will be used to evaluate the changes from entry to 4 or 12 weeks in CD4 and CD8 cell counts and percentages and levels of plasma-associated HIV-1 ribonucleic acid (RNA). Descriptive statistics for biomarkers will be reported using mean, standard deviation, median, and range. Linear regression analysis and correlation coefficient analysis will be performed to examine the association between change from baseline in a specific biomarker and study covariates.

    Time frame: Up to 5 years after completion of study treatment

  5. Levels of Notch target and regulatory gene products

    Will assess baseline levels of Notch target and regulatory gene products as a target of Nirogacestat activity. Notch target and regulatory gene expression at baseline will be summarized using descriptive statistics, and data visualization will be performed using principal component analysis and T-distributed stochastic neighbor embedding (t-SNE) plots. Linear and generalized linear models will be used to examine the association between expression level and study covariates. When multiplicity adjustment is needed, Bonferroni correction and false discovery rate approaches will be considered.

    Time frame: Baseline up to 5 years after completion of study treatment

Other outcomes

  1. Tumor-associated Kaposi sarcoma-associated herpesvirus (KSHV) latent and lytic gene expression

    Will assess the effect of Nirogacestat on tumor-associated KSHV latent and lytic gene expression. To evaluate the relationship between clinical response and quantitative measures of KSHV/human herpesvirus (HHV)-8 and HIV viral load, these measures will be tested to determine if they are normally distributed. If the data does not meet the assumptions of normality, the data will be transformed for analysis purposes. Analysis of variance will be used to assess the relationship between qualification of baseline levels of KSHV/HHV-8, HIV viral load, and response. Spearman rank correlation analysis will be used to evaluate the relationship between the qualification of baseline KSHV/HHV-8, HIV viral load and time to progression, and response duration.

    Time frame: Up to 5 years after completion of study treatment

  2. Activation of Notch target genes and Notch regulatory genes

    Will assess effects of Nirogacestat on activation of Notch target genes and Notch regulatory genes.

    Time frame: Up to 5 years after completion of study treatment

  3. Tumor-associated endothelial-mesenchymal transition

    Will assess effects of Nirogacestat on tumor-associated endothelial-mesenchymal transition. Endothelial-mesenchymal transition will be assessed from scRNAseq. The following markers will be measured. Endothelial markers decreasing over time: CDH5 (VE-cadherin), PECAM1 (CD31), VWF (von Willebrand Factor), TEK (TIE2); Mesenchymal markers increasing over time: ACTA2 (a-SMA), VIM (vimentin), S100A4 (FSP-1), FN1 (Fibronectin); Master regulators of EMT increasing over time: SNAI1 (Snail), SNAI2 (Slug), TWIST1, ZEB1, ZEB2, LEF1.

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  4. Peak plasma of Nirogacestat in KS patients

    For pharmacokinetic analysis, 20 samples will be used (10 from responders and 10 from non-responders) to estimate peak plasma level.

    Time frame: Cycle 1 pre-dose, 0.5, 1.5, and 3 hours post-first dose and Cycle 2 day 1, pre-dose (one cycle=28 days)

  5. AUCs of Nirogacestat in KS patients

    For pharmacokinetic analysis, 20 samples will be used (10 from responders and 10 from non-responders) to estimate area under the curve (AUC)s such as AUC0-last and AUC0-∞, clearance, half-life, time of maximum concentration, and concentration maximum.

    Time frame: Cycle 1 pre-dose, 0.5, 1.5, and 3 hours post-first dose and Cycle 2 day 1, pre-dose (one cycle=28 days)

  6. Tissue biomarkers at progression by single cell transcriptomics or single cell RNA sequencing (scRNAseq)

    Will assess effects of Nirogacestat on tissue biomarkers at progression by single cell transcriptomics or scRNAseq. Descriptive statistics will be used for results of scRNAseq for 20 samples (10 samples from responders and 10 samples from non-responders). Differential expression analysis will be performed and visualization using volcano plot, boxplot, t-SNE will be displayed.

    Time frame: Up to 5 years after completion of study treatment

  7. Tissue biomarkers by multiplex immunohistochemistry (IHC)

    Will assess effects of Nirogacestat on tissue biomarkers by multiplex IHC. Descriptive statistics will be used for results of multiplex IHC for 20 samples (10 samples from responders and 10 samples from non-responders). Differential expression analysis will be performed and visualization using volcano plot, boxplot, t-SNE will be displayed. For multiplexed IHC analysis, mean fluorescent intensity for each biomarker will be obtained by time point and change from baseline will be calculated and summarized using descriptive statistics.

    Time frame: Baseline and after 28 days of therapy

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Feb 2030, 40 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 20, 2026
StartActual
Oct 13, 2026was Sep 2026
Primary completionEst.
Feb 17, 2030
CompletionEst.
Feb 17, 2030
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 20, 2026
Sites
Siteman Cancer Center at Washington University is now Recruiting
Oct 20, 2026
Start date
Sep 17, 2026→Oct 13, 2026 (actual)
Oct 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Siteman Cancer Center at Washington University · St Louis, United StatesContact added i•••@siteman.wustl.edu · •••3606Contact added (no phone or email listed)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Not yet recruiting→Recruiting
    Siteman Cancer Center at Washington University is now Recruiting
    Start date Sep 17, 2026→Oct 13, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Siteman Cancer Center at Washington University · St Louis, United StatesContact added i•••@siteman.wustl.edu · •••3606Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07539454
Lead sponsor
AIDS Malignancy Consortium
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Oct 13, 2026
Primary completion
Feb 17, 2030 (estimated)
Completion
Feb 17, 2030 (estimated)
Last update
Oct 20, 2026

Study contacts

Lee Ratner
principal investigator · AIDS Malignancy Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirogacestat

Start the discussion